title: Multiple valve operation for advanced valvular heart disease: results and risk factors in 513 patients.
abstract: To assess the results and incremental risk factors affecting outcome after multiple-valve operation in the early blood cardioplegia era of cardiac surgery, follow-up data (mean +/- SD 3.1 +/- 2 years) were obtained on 97% of 513 patients (mean age +/- SD 58.8 +/- 10.5 years) who underwent a multiple-valve procedure between June 1976 and August 1985. Preoperatively 41% of patients were in New York Heart Association functional class III and 54% in class IV. Three groups accounted for 98.6% of the patients: 57.7% had an aortic and mitral valve procedure, 29% had a mitral and tricuspid valve procedure and 11.9% had a triple-valve procedure. The overall hospital mortality rate was 12.5% and overall 5-year survival rate was 67.1%. Hazard function analysis for all deaths revealed systolic pulmonary artery pressure (p less than 0.0001), age (p = 0.005), triple valve procedure (p less than 0.005), concomitant coronary bypass operation (p less than 0.005) and prior cardiac surgery (p less than 0.002) as the significant incremental risk factors predicting decreased survival in the early hazard phase; diabetes (p less than 0.005) predicted decreased survival in the late hazard phase. Postoperatively the condition of 80% of the patients improved to functional class I or II; only 0.6% remained in functional class IV. The 5-year rate of freedom from late combined valve-related morbidity was 81.7% and that of freedom from late combined valve-related morbidity and mortality was 71.7%. These results demonstrate excellent clinical improvement and late survival after multiple valve operation in patients with advanced valvular heart disease, justifying aggressive surgical therapy in these patients.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Surgery, New York University Medical Center, New York 10016.
authors.forename: A C
authors.initials: AC
authors.lastname: Galloway
authors.forename: E A
authors.initials: EA
authors.lastname: Grossi
authors.forename: F G
authors.initials: FG
authors.lastname: Baumann
authors.forename: C L
authors.initials: CL
authors.lastname: LaMendola
authors.forename: G A
authors.initials: GA
authors.lastname: Crooke
authors.forename: L J
authors.initials: LJ
authors.lastname: Harris
authors.forename: S B
authors.initials: SB
authors.lastname: Colvin
authors.forename: F C
authors.initials: FC
authors.lastname: Spencer
mesh_terms: D001705:Bioprosthesis; D005260:Female; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000401:mortality / Q000601:surgery*; D006350:Heart Valve Prosthesis / Q000401:mortality*; D006351:Heart Valves / Q000601:surgery; D017052:Hospital Mortality; D006801:Humans; D006976:Hypertension, Pulmonary / Q000453:epidemiology; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome